European Journal of Cancer
Volume 37, Issue 18 , Pages 2297-2301 , December 2001

Future trends in the treatment of brain tumours

  • A.A Brandes

      Affiliations

    • EORTC-Brain Tumor Group, Quality Assurance Subcommittee, Padova, Italy
    • Corresponding Author InformationCorresponding author at: Medical Oncology Department, 6° Piano Monoblocco, Azienda Ospedale Università, Via Giustiniani 2, 35100 Padova, Italy Tel.: +39-04-9821-2970; fax: +39-04-9821-2931
    • ,
  • D Lacombe

      Affiliations

    • EORTC Data Center Medical Advisor, Brussels, Belgium
    • ,
  • C Vecht

      Affiliations

    • EORTC-Brain Tumor Group, Chairman, The Hague, The Netherlands

Received 22 August 2001 ,Accepted 30 August 2001.

References 

  1. Kleiheus P, Cavenee WK, eds. Tumors of Nervous System. WHO. IACR Press, France, 2000.
  2. Cairncross JG, Ueki K, Zlatescu MC. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 1998;90:1473–1479
  3. Grossman SA, O'Neill A, Grunnet M, et al.  Phase III study comparing three cycles of infusional BCNU/cisplatin followed by radiation with radiation and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme (ECOG 2394-SWOG 9508). Proc. Am. Soc. Clin. Oncol. 2000;19:158a
  4. Brada M. Current approaches to radiation therapy for malignant gliomas. Front Radiat. Ther. Oncol. 1999;33:139–149
  5. Laperriere NJ, Leung PM, McKenzie S, et al.  Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 1998;41:1005–1011
  6. Kleinberg L, Grossman SA, Piantadosi S, et al.  Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer in newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 1999;17:2593–2603
  7. Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-Oncol. 2000;4:221–228
  8. Medical Research Council Brain Tumor Working Party . Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma (A Medical Research Council Trial). J. Clin. Oncol. 2001;19:509–518
  9. DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma (who benefits from adjuvant chemotherapy?). Ann. Neurol. 1998;44:691–695
  10. Yung WK, Albright RE, Olson J, et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer. 2000;83:588–593
  11. Brandes AA, Ermani M, Basso U, et al.  Temozolomide as a second-line systemic regimen in recurrent high-grade glioma (a phase II study). Ann. Oncol. 2001;12:255–257
  12. Stupp R, Ostermann S, Dietrich PY, et al.  Daily temozolomide (TMZ) and concomitant radiation followed by adjuvant TMZ for newly diagnosed glioblastoma multiforme (GBM). Neuro-Oncology. 2000;2:208
  13. Brandes AA, Palmisano V, Pasetto LM, Basso U, Monfardini S. High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest. 2001;19:41–48
  14. Esteller M, Garcia-Foncillas J, Andion E, et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl. J. Med. 2000;343:1350–1354
  15. Brandes AA, Ermani M, Basso U, et al.  Procarbazine prior to and concomitant with BCNU in patients with glioblastoma at first relapse (a phase II study). Proc. Am. Soc. Clin. Oncol. 2001;20:61a
  16. Friedman AH, Cokgor I, Colvin OM, et al.  Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 2000;18:3522–3528
  17. Quinn JA, Tourt-Uhlig S, Rich JN, et al.  Phase II trial of BCNU plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Proc. Am. Soc. Clin. Oncol. 2001;20:64a
  18. Tolcher AW, Felton S, Gerson SL, et al.  Persistent and marked inactivation of O6-alkylguanine-DNA alkyltransferase (AGAT), a mechanism of resistance to alkylators, with protracted low-dose oral schedules of temozolomide. Proc. Am. Soc. Clin. Oncol. 2000;19:175a
  19. Balmaceda C, De Rosa CM, Peterson K, et al.  Feasibility of a bid regimen of temodar in the treatment of recurrent malignant gliomas (RMG). Neuro-Oncology. 2000;2:16
  20. Denis LJ, Tolcher A, Figueroa JA, et al.  Protracted daily administration of Temozolomide is feasible (a Phase I and pharmacokinetic-pharmacodynamic study). Proc. Am. Soc. Clin. Oncol. 2000;19:202a
  21. Figueroa JA, Tolcher A, Denis LJ, et al.  Protracted cyclic administration of temozolomide is feasible; a phase I, pharmacokinetic and pharmacodynamic Study. Proc. Am. Soc. Clin. Oncol. 2000;19:222a
  22. Brock CS, Newlands ES, Wedge SR, et al.  Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363–4372
  23. Cairncross JG, Swinnen L, Bayer R, et al.  Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Oligodendroglioma Study Group. Neuro-Oncology. 2000;2:114–119
  24. Van Den Bent MJ, Keime-Guibert F, Brandes AA, et al.  Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology. 2001;57:340–342
  25. Chinot OL, Honore S, Dufour H, et al.  Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol. 2001;19:2449–2455
  26. Karim AB, Maat B, Hatlevoll R, et al.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma (European Organization for Research and Treatment of Cancer (EORTC) Study 22844). Int. J. Radiat. Oncol. Biol. Phys. 1996;36:549–556
  27. Friedman AH, Cokgor I, Kerby T, et al.  Phase II treatment of anaplastic oligodendroglioma and low grade glioma with temozolomide. Proc. Am. Soc. Clin. Oncol. 1999;18:150a
  28. Viviers L, Brada M, Hines F, et al.  A phase II trial of primary chemotherapy with temozolomide in patients with low-grade cerebral gliomas. Proc. Am. Soc. Clin. Oncol. 2000;19:167a
  29. Reijneveld JC, Sitskoorn MM, Klein M, Nuyen J, Taphoorn MJ. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology. 2001;5:618–623
  30. Brandes AA, Rigon A, Monfardini S. Radiotherapy of the brain in elderly patients. Contra. Eur. J. Cancer. 2000;4:447–451
  31. Abrey LE, Yahalom J, DeAngelis LM, et al.  Treatment for Primary CNS lymphoma (the next step). J. Clin. Oncol. 2000;18:3144–3150
  32. Soussain C, Suzan F, Hoang-Xuan K, et al.  Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol. 2001;19:742–749

PII: S0959-8049(01)00301-X

doi: 10.1016/S0959-8049(01)00301-X

European Journal of Cancer
Volume 37, Issue 18 , Pages 2297-2301 , December 2001

Article Tools